文献速递糖尿病

糖尿病视网膜病变分期与2型糖尿病患者主要下肢动脉疾病风险的关系

Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2020-09-02

前瞻性队列纳入1320例无下肢动脉疾病(LEAD)史的2型糖尿病患者,按基线视网膜病变分期(无、非增殖性、增殖性)评估主要LEAD(截肢或血运重建)风险。中位随访7.1年,94例(7.1%)发生主要LEAD,发病率随视网膜病变加重而升高;非增殖性和增殖性视网膜病变均与主要LEAD独立相关,且视网膜病变可改善LEAD风险分层。

要点

  • 视网膜病变越重,主要LEAD发病率越高(无、非增殖性、增殖性分别为5.5、14.6、20.1/1000人年)。
  • 非增殖性和增殖性视网膜病变均独立增加主要LEAD风险(校正HR分别为2.31和3.14)。
  • 视网膜病变可提升LEAD风险预测的C统计量、IDI和NRI,提示其可作为LEAD预测指标。

核心结论

  • 糖尿病视网膜病变分期与主要LEAD之间存在独立的剂量反应关系。
  • 视网膜病变可为LEAD风险分层提供增量预后信息,提示其可作为LEAD的预测指标。

研究设计与样本

  • 前瞻性队列研究,纳入1320例基线无LEAD史的2型糖尿病患者。
  • 基线时对视网膜病变进行分期:无、非增殖性或增殖性。
  • 采用Cox回归模型计算基线视网膜病变分期与随访期间主要LEAD(下肢截肢或血运重建)的风险比(HR)及95%CI。

主要发现

  • 中位随访7.1年,94例(7.1%)发生主要LEAD,发病率为9.6/1000人年(95%CI 7.8-11.7)。
  • 主要LEAD发病率随视网膜病变加重而升高:无为5.5(95%CI 3.9-7.8)/1000人年,非增殖性为14.6(95%CI 11.1-19.3)/1000人年,增殖性为20.1(95%CI 11.1-36.3)/1000人年。
  • 非增殖性视网膜病变与主要LEAD相关(校正HR 2.31,95%CI 1.43-3.81,P=0.0006),增殖性视网膜病变亦相关(校正HR 3.14,95%CI 1.40-6.15,P=0.007)。
  • 各亚组间未观察到异质性。
  • 视网膜病变在传统危险因素基础上提升了LEAD风险的C统计量(+0.023,95%CI 0.003-0.044,P=0.02)、IDI(0.209,95%CI 0.130-0.321,P<0.001)和NRI(0.562,95%CI 0.382-0.799,P<0.001)。

临床怎么用

  • 对2型糖尿病患者,可根据视网膜病变分期识别主要LEAD高危人群,加强下肢动脉疾病筛查与随访。
  • 视网膜病变分期可作为LEAD风险预测的辅助信息,纳入综合风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the association between diabetic retinopathy stages and lower-extremity arterial disease (LEAD), its prognostic value, and the influence of potential contributors to this relationship in a prospective cohort of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Diabetic retinopathy was staged at baseline as absent, nonproliferative, or proliferative. A Cox regression model was fitted in order to compute the hazard ratio (HR) (95% CI) for major LEAD (lower-limb amputation or revascularization) during follow-up by baseline retinopathy stages. The retinopathy-LEAD association was assessed in subgroups by age, sex, diabetes duration, HbA1c, systolic blood pressure, diabetic kidney disease, smoking, and macrovascular disease at baseline. The performance of retinopathy in stratifying LEAD risk was assessed by using the C statistic, integrated discrimination improvement (IDI), and net reclassification improvement (NRI). RESULTS: Among 1,320 participants without a history of LEAD at baseline, 94 (7.1%) developed a major LEAD during a 7.1-year median follow-up (incidence rate 9.6 per 1,000 person-years [95% CI 7.8-11.7]). The LEAD incidence rate (per 1,000 person-years) increased as retinopathy worsened: it was 5.5 (95% CI 3.9-7.8) in participants in whom retinopathy was absent, 14.6 (11.1-19.3) in those with nonproliferative retinopathy, and 20.1 (11.1-36.3) in those with proliferative retinopathy. Nonproliferative retinopathy (adjusted HR 2.31 [95% CI 1.43-3.81], P = 0.0006) and proliferative retinopathy (3.14 [1.40-6.15], P = 0.007) remained associated with major LEAD. No heterogeneity was observed across subgroups. Retinopathy enhanced the C statistic (+0.023 [95% CI 0.003-0.044], P = 0.02), IDI (0.209 [0.130-0.321], P < 0.001), and NRI (0.562 [0.382-0.799], P < 0.001) values for risk of LEAD, beyond traditional risk factors. CONCLUSIONS: An independent dose-response relationship was identified between diabetic retinopathy stages and major LEAD. Retinopathy yielded incremental prognostic information for stratifying risk of LEAD, suggesting its usefulness as a predictor of LEAD.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Foussard N, Saulnier PJ, Potier L, et al. Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care. 2020. PMID: 33055101. doi:10.2337/dc20-1085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。